ArticleNanotheranostics2026
Liposomal J-Aggregates of Indocyanine Green as a Multifunctional Contrast Agent for Photoacoustic Imaging and Photothermal Therapy.
Article in Nanotheranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
One of the major barriers to further clinical adoption of photoacoustic imaging (PAI) and photothermal therapy (PTT) is a lack of versatile and multi-faceted contrast agents. While indocyanine green (IcG) has gained considerable attention as a promising contrast agent, it is severely limited by rapid clearance time, low photostability, and a peak absorbance wavelength that coincides with hemoglobin. Herein, Liposomal J-aggregates of Indocyanine green (LJA) are presented as a superior alternative to generic IcG. They are a facilely produced, biodegradable nanoparticle offering advantageous physiochemical properties. J-aggregation results in a redshifted peak absorbance of increased magnitude and higher photostability compared to IcG. Liposome encapsulation increases circulation time leading to improved tumor uptake. Monte Carlo modeling of light interaction with tissue suggests that these improved optical properties make LJA a better contrast agent for PTT not only at longer wavelengths like 852nm and 890nm, but also at the commonly available and widely used 808nm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.